CBS12 Press Release 12.2.13 – final
Nexalin Technology is being presented to lead psychiatrists at Princeton Behavioral Health in Princeton New Jersey, associated with the Princeton healthcare system at Princeton University.
Mark White, Nexalin VP of Operations, attends the National Convention for the National Alliance on Mental Illness (NAMI) to discuss a partnership with Nexalin Technology.
Nexalin Technology – Becoming The Most Efficient DRUG -FREE Intervention to Opiate Addiction
Nexalin CEO Randall Letcavage and medical advisory board member E. Patrick Miller meet with CME Acuity principal owners David Rothman and Joel Bradus to welcome them as a new distributor of Nexalin products in the New York City metro area. The CME acuity team brings over 30 years of experience in the health care industry. They…
E. Patrick Miller is a renowned Clinical Sports Psychologist who has worked and consulted in a myriad of clinical settings as an Expert in Community Mental Health. He is a pioneer in developing state of the art Treatment Centers in Community Mental Health, Substance Abuse, Addictions Recovery and the Dual Diagnosis Population in Residential Treatment…
Tustin, CA – Nexalin is proud to announce the addition of Comprehensive Pain Relief Group (CPRG) to our expanding health care provider network. In the coming weeks ahead, Nexalin treatments will be available in two new locations (Torrance and Fresno, CA). About CPRG “Comprehensive Pain Relief Group (CPRG)/GS Medical Center were formed by Gregory A….
With Obama passing the BRAIN Initiative (Brain Research through Advancing Innovative Neurotechnologies), the challenge is to help fund new innovative technologies that will help better understand the brain and the disorders that effect….
Cranial electrotherapy stimulation (CES) is reported to be effective treatment for anxiety, a major presenting symptom among chemically dependent patients. In this study, 40 inpatient alcohol and/or poly-drug users were given CES or sham CES in a double blind design. An additional 20 patients served as norlmla hospital routine controls. Dependent measures of anxitety were the Profile of Mood States, the Institute for Personality and Ability Testing Anxiety Scale, and the State/Trait Anxiety Index. CES-treated patients showed significantly greater improvement on all anxiety measures than did either control group. There were no differences in response between older and younger patients, or between the primary drug or alcohol users. No placebo effect was found on any of our measures. It is concluded that CES is a clinically significant addition to the treatment regimen for this patient population.
The number of people in this country exhibiting symptoms of depression and anxiety continues to grow and is projected to continue growing through the next decade at least. The symptoms of these disorders cause substantial distress for the sufferers and their families and cost society dearly each year in lost time and suboptimal job performance.